The synthetic versions mimic the biological activity of the natural NGF.

Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.

The neurotrophic-like biological activity may be that of NGF.

NGF mediates many of its effects through a receptor system (NGF receptor system).

The synthetic ADESH was equally active as the fragment of the native NGF.

Also provided is a method for preparing Met-less NGF polypeptides.

Similarly, the prepro regions can be derived from those neurotrophin molecules of the NGF/BDNF family including but not limited to NGF, BDNF, NT-3, and NT-4.

The preparation methods of the transgenic rodents, the methods of utilizing the transgenic animals to prepare NGF beta mutant proteins and the resulting NGF beta mutant proteins are provided.

Antibodies versus ADESH react with natural NGF having 116 amino acids.

Gene expression was compared before and after withdrawal of serum or NGF.

The invention provides novel caninized anti-NGF antibodies (such as caninized anti-NGF antagonist antibodies and antigen binding proteins), and polynucleotides encoding the same.

The cyclic compounds of the present invention may be structural analogs of NGF or small monomeric, dimeric or polymeric cyclic compounds that mimic the β-turn regions of NGF.

Use of an anti-NGF antibody capable of inhibiting the binding between NGF and TrkA, capable of blocking the biological activity of TrkA for the preparation of a medicament for treating and/or preventing chronic pain.

Embodiments of the invention also pertain to the use of anti-NGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with NGF.

The present invention relates to the use of NGF for the preparation of a medicament for the cure and/or prevention of reactive gliosis and therapeutic methods for the cure and/or prevention of reactive gliosis by NGF administration.